Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if NERV is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
10 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
58 filers reported a long position in NERV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FEDERATED HERMES, INC. | $25.9M | 4.7M | -8.7% |
| Jupiter Topco LLC | $24.3M | 4.4M | — |
| Vivo Capital, LLC | $24M | 4.3M | Unchanged |
| BALYASNY ASSET MANAGEMENT L.P. | $23.6M | 4.3M | 0% |
| Logos Global Management LP | $18.3M | 3.3M | +2.3% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $13.1M | 2.4M | Unchanged |
| BlackRock, Inc. | $12.4M | 2.2M | +258.6% |
| Ally Bridge Group (NY) LLC | $12.1M | 2.2M | +31.4% |
| Foresite Capital Management VI LLC | $11M | 2M | -0.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.5M | 1.9M | +2.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.